The efficacy of combined treatment with the BRAF inhibitor dabrafenib and the MEK 1/2 inhibitor trametinib in patients with metastatic BRAF V600E-mutated NSCLC has been demonstrated in an open-label phase II trial (NCT01336634) including previously pre-treated (cohort B) and untreated patients (cohort C). This evidence concerns the gene BRAF and non-small cell lung carcinoma.